Notify me when Bihua Chen files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| HLXB | Helix Acquisition Corp. II | Class A ordinary shares, $0.0001 par value per share | 32% | $81,352,890 | 7,389,000 | Bihua Chen | 28 Feb 2025 | ||
| BridgeBio Oncology Therapeutics, Inc. | Common Stock | 23% | 17,878,594 | Bihua Chen | 11 Aug 2025 | ||||
| MLTX | MoonLake Immunotherapeutics | Class A Ordinary Shares | 3.1% | $108,084,177 | 1,994,173 | Chen Bihua | 30 Sep 2025 | ||
| BMEA | Biomea Fusion, Inc. | Common Stock | 1.5% | $2,143,436 | -$5,295,734 | 1,060,792 | -71% | Chen Bihua | 22 Oct 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|